BioVaxys Technology Corp. Engages Enclave Capital LLC
BioVaxys Technology Corp. is excited to share its partnership with Enclave Capital LLC, which will serve as an agent for a brokered private placement financing offer. This collaboration aims to advance the Company's innovative biotechnology initiatives.
The Role of Enclave Capital
Enclave Capital LLC has been engaged to work alongside D12 Capital Markets Inc. and Foundation Markets Inc. as part of the effort surrounding the brokered private placement offering. The collective team's goal is to secure funding that will support BioVaxys's vision of revolutionizing immunotherapy.
Details of the Offering
Upon the successful completion of the offering, Enclave will earn a cash fee that amounts to 8% of the total proceeds raised through investments. As a part of this agreement, BioVaxys will also pay Enclave a fixed fee of $10,000.
Offering Terms and Conditions
The offerings are subject to compliance with applicable regulations, specifically aligning with National Instrument 45-106 – Prospectus Exemptions. The units associated with this offering will be available to investors across various provinces, excluding certain areas.
BioVaxys's Unique Approach to Immunotherapy
BioVaxys is a clinical-stage biopharmaceutical company focused on improving the lives of patients through cutting-edge immunotherapies. The company leverages its proprietary DPX™ immune-educating technology, as well as its HapTenix© tumor cell construct platform, to develop treatments for a variety of conditions, including cancer and infectious diseases.
Key Projects in Development
BioVaxys's pipeline includes prominent candidates such as maveropepimut-S (MVP-S), which is currently in Phase IIB clinical development targeting advanced relapsed-refractory diffuse large B cell lymphoma and platinum-resistant ovarian cancer. This therapy has shown promise by delivering antigenic peptides that generate a robust immune response tailored to combating cancer.
Company Overview
As a publicly traded entity, BioVaxys common shares are found on the CSE under the symbol 'BIOV,' trading also on the Frankfurt Bourse as 5LB and on the OTC Markets in the U.S. under the symbol 'BVAXF'. With a commitment to advancing biopharmaceutical innovation, BioVaxys aims to forge a path towards effective treatments for complex health issues.
Contact Information
The CEO of BioVaxys, James Passin, is actively overseeing the progress of the company. Stakeholders and potential investors can reach out via phone at +1 740 358 0555 for inquiries regarding the latest investment opportunities and company updates.
Frequently Asked Questions
What is the main purpose of the partnership with Enclave Capital?
The partnership is aimed at facilitating a brokered private placement offering that will support the funding of BioVaxys's innovative immunotherapy developments.
What kind of fees will Enclave Capital receive?
Enclave Capital will receive a cash fee of 8% of the total proceeds from the offering, in addition to a fixed fee of $10,000.
Where can the offering units be purchased?
The offering units are available to investors across multiple provinces, barring jurisdictions that are excluded under specific regulations.
What innovative therapies does BioVaxys develop?
BioVaxys focuses on developing immunotherapies targeting various conditions through its advanced technology platforms, primarily for cancer treatments and infectious diseases.
How can I contact BioVaxys for more information?
Interested parties can reach out directly to James Passin, the CEO, at +1 740 358 0555 for inquiries or further information on the company’s initiatives.
